We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Urodynamix Technologies Ltd. | TSXV:URO | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
With the sale of the medical device business now completed, Heppell and Raffa have aggressively cut back on expenses and are actively engaged in pursuing new business opportunities for the Company. Announcements in this regard will be made as these activities progress.
Steps have been commenced to schedule the 2011 Annual General Meeting of the shareholders of the Company. The Company will provide further particulars when the meeting and agenda have been finalized.
Forward-looking Statements:
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Urodynamix Technologies Ltd. Jim Heppell Chief Executive Officer Jheppell@lionscapital.com www.urodynamix.com
1 Year Urodynamix Technologies Ltd. Chart |
1 Month Urodynamix Technologies Ltd. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions